Thyrocare®

The Trust. The Truth.

07th April 2021

The Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip ID: THYROCARE

The Listing Department
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Scrip Code: 539871

Dear Sirs,

Sub: Intimation under Regulation No. 30 & 36 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

We would like to make the following announcements and business update for the knowledge of our shareholders, investors, and general public:

1. Q4 of FY 21 has witnessed motivating numbers and increased turnover of COVID RT-PCR testing. The aggregate revenue for the quarter ended 31 March 2021, has increased by about **46% YOY**. The continued momentum due to our aggression in COVID RT-PCR testing, non COVID business coming back to normalcy, our other strategic initiatives taken during and after pandemic, and quick execution by our operations team, has resulted in a healthy growth during the current financial year, coupled with sustained EBITDA and profit margins

2. We have enhanced the capacity to perform RT-PCR tests to 15,000 swabs a day in our laboratory at Navi Mumbai and also to 5,000 swabs a day in the laboratory at Gurgaon and which commenced operations in October 2020.

3. Our new COVID testing facility at Bangalore is approved by NABL. It also has been built with an ability to perform 5,000 RT-PCRs a day.

4. We intend to enhance the capacity, as the demand raises, if it raises, in all three COVID testing locations to 25,000 swabs a day each

5. Keeping in mind, the potential of COVID testing, our Kolkata facility is also getting prepared for a similar size, and will be operational by end of Q2-2022.

6. Thyrocare has done more than 1 million COVID tests as on 31.03.2021

7. With non COVID tests coming back to track, we anticipate a need for more capacity and facilities. We have commenced operations at our new Regional Processing Laboratories at Lucknow and Cochin, and we intend to enhance our operations at Regional Processing Laboratories by extension

Thyrocare Technologies Limited

of our existing setup in Mumbai and New Delhi, to ensure quickest turnaround for core pathology business.

8. Particularly, for the last 20 days, we have evidenced significant rise in the testing across all our laboratories and our laboratory team has efficiently ensured to manage the rising volumes and is getting ready for surges country-wide if there are any.

The financial statements for the quarter and year ended 31 March 2021 are under review by our statutory auditors and we will file our detailed financial release post approval by the Audit Committee and the Board, sooner.

Since convening physical general meeting is rendered impossible on account of pandemic Covid-19, we are unable to communicate with our shareholders in an effective manner, as also meet their queries.Therefore, in terms of the Clauses 30 & 36 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby apprise you and all our shareholders / stakeholders of the above material developments having a bearing on our performance / operations / finance, which information we consider as 'price sensitive' concerning our listed securities.

We request you to kindly take on record the above. We are also posting this intimation on our web site.

Thanking You.

Yours Faithfully,
For Thyrocare Technologies Limited

RamjeeDorai
Company Secretary and Compliance Officer

Thyrocare Technologies Limited